The FDA said it plans to include aging and longevity among the topics highlighted in an upcoming update to its Focus Areas of Regulatory Science (FARS) report. FDA Chief Scientist Steven Kozlowski told the 13th Aging Research & Drug Discovery Meeting that the agency is looking for shared, pre-competitive endpoints that could support feasible clinical trial designs. Acting FDA Chief of Staff Lowell M. Zeta also framed healthspan and longevity as priorities for both the FDA and HHS. The update signals a clearer regulatory science roadmap as longevity therapeutics move toward broader clinical evaluation.